1
Robin Clark, Anthony Davies: Baculovirus expression system and method for high throughput expression of genetic material. Onyx Pharmaceuticals, Gregory Giotta, May 1, 2001: US06225060 (118 worldwide citation)

The present invention provides novel recombinant baculovirus expression systems for expressing foreign genetic material in a host cell. Such expression systems are readily adapted to an automated method for expression foreign genetic material in a high throughput manner. In other aspects, the presen ...


2
Robin Clark, Joanna Albala, Ian McConnell, Ken Franke: Selection method for producing recombinant baculovirus. Onyx Pharmaceuticals, Gregory Giotta, August 6, 2002: US06428960 (85 worldwide citation)

The present invention provides a novel method for producing recombinant baculoviruses expressing genes of interest by inserting a selectable marker gene, specifically the puromycin resistance (pac) gene, adjacent to the gene of interest into the baculovirus genome, and selecting for viruses that exp ...


3
James R Erickson, Scott Powers: Reverse two-hybrid method. ONYX Pharmaceuticals, Gregory Giotta, Tracy Dunn, June 11, 1996: US05525490 (49 worldwide citation)

The reverse two-hybrid method has been designed to provide a practical and efficient means of utilizing yeast cell-based assays to screen for molecules that can inhibit protein-protein interactions of interest. Existing two-hybrid systems involve reconstitution in yeast of a transcriptional activato ...


4
Francis McCormick: Cytopathic viruses for therapy and prophylaxis of neoplasia. ONYX Pharmaceuticals, Gregory Giotta, Timothy E Torchia, October 14, 1997: US05677178 (44 worldwide citation)

Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able t ...


5
James R Bischoff, Maria J Fernandez Sarabia: Bcl-2 and R-ras complex. Onyx Pharmaceuticals, Gregory Giotta, Tracy Dunn, July 23, 1996: US05539085 (33 worldwide citation)

The invention provides compositions and methods for screening for agents which are modulators of bcl-2 function and can modulate bcl-2-mediated apoptosis and/or modulate neoplastic and immune conditions dependent upon bcl-2 function. The invention also provides a composition comprising a substantial ...


6
Robert Ferris, Walter J Laird: Method of purifying toxin conjugates using hydrophobic interaction chromatography. Cetus Corporation, Dianne Reed, Gregory Giotta, Albert P Halluin, September 13, 1988: US04771128 (24 worldwide citation)

A method of isolating and purifying toxin conjugates using hydrophobic interaction chromatography. Crude conjugate mixtures are sized to remove unconjugated toxin, and loaded onto a column filled with a suitable hydrophobic gel. Elution is effected with salt solutions of decreasing ionic strength, w ...


7
Francis McCormick: Cytopathic viruses for therapy and prophylaxis of neoplasia. Onyx Pharmaceuticals, Gregory Giotta, January 5, 1999: US05856181 (19 worldwide citation)

Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able t ...


8
John F Lyons, Gideon Bollag: RAF-MEK-ERK pathway inhibitors to treat cancer. Onyx Pharmaceuticals, Gregory Giotta, December 11, 2007: US07307071 (17 worldwide citation)

Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.


9
Francis McCormick: Cytopathic viruses for therapy and prophylaxis of neoplasia. ONXY Pharmaceuticals, Gregory Giotta, October 26, 1999: US05972706 (13 worldwide citation)

Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able t ...


10
Leisa Johnson, Ali Fattaey, Terry Hermiston: Oncolytic adenovirus. Onyx Pharmaceuticals, Gregory Giotta, February 21, 2006: US07001596 (8 worldwide citation)

Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsi ...